About this Abstract |
| Meeting |
2026 TMS Annual Meeting & Exhibition
|
| Symposium
|
Magnesium Technology 2026
|
| Presentation Title |
Exogenously Controlling Degradation Behavior of Bioabsorbable Mg Utilizing Chelation Therapy |
| Author(s) |
Mitchell Connon, Roger Guillory II |
| On-Site Speaker (Planned) |
Mitchell Connon |
| Abstract Scope |
Chelation therapy is an FDA-approved clinical treatment for heavy metal intoxication. Chelating agents bind metal ions forming urinary excretable soluble complexes. Their effect on bioabsorbable metal degradation via physiological administration has not been investigated. Here a commercially available Mg alloy, AZ31, was explored for both in vitro and in vivo studies. Treatment groups of mice implanted subcutaneously with AZ31 received a continuous dose of calcium-disodium-ethylenediaminetetraacetic saline solution for 30 days. Micro-CT scans of gas pocket formation surrounding the implant were used to serially quantify degradation via hydrogen evolution, and explants were measured for degradation at study endpoints. In vitro experiments were performed to investigate the influence of chelating agents on the corrosion product layer morphology. It was found from both in vivo and in vitro experiments that the administration of chelating agents had a major influence on degradation behavior and surface product composition of AZ31 implants. |
| Proceedings Inclusion? |
Planned: |
| Keywords |
Biomaterials, Magnesium, |